The effect of supplemental oxygen and continuous positive airway pressure withdrawal on endocan levels
Sleep and Breathing · 2024
DOI: 10.1007/s11325-024-03120-2 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Sleep and Breathing, 2024. Verfasst von Chris D Turnbull und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS, Foundation Trust, Oxford, UK. christopher.turnbull@ouh.nhs.uk. Hauptthemen laut MEDLINE: Proteoglycans, Continuous Positive Airway Pressure, Sleep Apnea, Obstructive, Cross-Over Studies. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Endocan is a biomarker of endothelial dysfunction, which is a precursor to cardiovascular disease. Obstructive sleep apnoea (OSA) is associated with elevated endocan levels but the effects of treatment on endocan levels in OSA are not fully established. We aimed to determine whether endocan levels could be detected by immunoassay and to determine the effect of supplemental oxygen during continuous positive airway pressure (CPAP) withdrawal on circulating endocan levels.
Methods
We conducted an exploratory analysis from a randomised controlled crossover study which included participants with OSA. Participants stopped their CPAP therapy and were randomised to receive either supplemental oxygen or sham for 14 nights before crossing over. Supplemental oxygen blocked the rise in blood pressure seen in the sham group. We analysed plasma endocan levels by immunoassay at baseline and after 14 nights of intervention in both groups.
Results
Twenty-five participants were included, with a total of 100 samples. Endocan levels were detectable at all time points in 22 participants (88%), and in 93 (93%) samples. Supplemental oxygen had no effect on endocan levels compared to sham (+ 0.52 ng/ml, 95%CI -0.21 to + 1.25, p = 0.16), and there was no significant difference in endocan levels from baseline to follow-up in either the sham (-0.30 ng/ml, 95%CI -0.89 to + 0.30, p = 0.31) or supplemental oxygen (+ 0.22 ng/ml, 95%CI 0.00 to + 0.44, p = 0.05) arm.
Conclusions
We have shown that endocan levels are detectable before and after CPAP withdrawal. However, we found no effect of supplemental oxygen following CPAP withdrawal on circulating endocan levels. Trial registration and date ISRCTN 17,987,510 19/02/2015.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS, Foundation Trust, Oxford, UK. christopher.turnbull@ouh.nhs.uk.
- Nuffield Department of Medicine, University of Oxford, Oxford, UK. christopher.turnbull@ouh.nhs.uk.
- NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK. christopher.turnbull@ouh.nhs.uk.
- Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
- Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS, Foundation Trust, Oxford, UK.
ORCID-Profile: Chris D Turnbull
Zitieren
APA
Turnbull, C. D., Stradling, J. R., Petousi, N., & Lassalle, P. (2024). The effect of supplemental oxygen and continuous positive airway pressure withdrawal on endocan levels. Sleep and Breathing. https://doi.org/10.1007/s11325-024-03120-2
Vancouver
Turnbull CD, Stradling JR, Petousi N, Lassalle P. The effect of supplemental oxygen and continuous positive airway pressure withdrawal on endocan levels. Sleep and Breathing. 2024. doi:10.1007/s11325-024-03120-2
BibTeX
@article{Turnbull2024,
author = {Turnbull, Chris D and Stradling, John R and Petousi, Nayia and Lassalle, Philippe},
title = {The effect of supplemental oxygen and continuous positive airway pressure withdrawal on endocan levels},
journal = {Sleep and Breathing},
year = {2024},
doi = {10.1007/s11325-024-03120-2}
}
EUVIMED